<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630825</url>
  </required_header>
  <id_info>
    <org_study_id>12068</org_study_id>
    <secondary_id>H9X-MC-GBCJ</secondary_id>
    <nct_id>NCT00630825</nct_id>
  </id_info>
  <brief_title>A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus</brief_title>
  <acronym>EGO</acronym>
  <official_title>The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study once weekly injections of LY2189265 compared to placebo on blood glucose by
      measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight
      Type 2 Diabetes Mellitus participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie [Kcal], 103 grams [g] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting [0]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles</measure>
    <time_frame>2 separate days in the week preceding the Baseline, Week 4, Week 8, and Week 16 visits.</time_frame>
    <description>Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of &lt;7% or ≤6.5%</measure>
    <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
    <description>Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of &lt;7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, 4, 8, and 16 weeks</time_frame>
    <description>LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Mean change from baseline in waist circumference (a measure of central obesity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and Dyspepsia Measured by Visual Analog Scale</measure>
    <time_frame>One week before and one week after each of the Baseline and Week 4 and Week 8 and Week 16 visits</time_frame>
    <description>Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores</measure>
    <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
    <description>Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Hypoglycemic Event</measure>
    <time_frame>Baseline through 4, 8, and 16 weeks</time_frame>
    <description>A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of &lt;50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hypoglycemia Per 30 Days</measure>
    <time_frame>Baseline through 16 weeks</time_frame>
    <description>Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipids</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</measure>
    <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
    <description>The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6-point scale ranging from 1 &quot;completely dissatisfied&quot; to 6 &quot;completely satisfied&quot;; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 &quot;all of the time&quot; to 4 &quot;none of the time&quot;; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 &quot;all of the time&quot; to 4 &quot;none of the time.&quot; These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</measure>
    <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
    <description>This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>Time zero to 168 hours after study drug administration at 4, 8, and 16 weeks</time_frame>
    <description>The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve [AUC] at steady state from time zero to 168 hours after study drug administration).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>1.0/2.0 milligram (mg) LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0/1.0 milligram (mg) LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5/1.0 milligram (mg) LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2189265</intervention_name>
    <arm_group_label>1.0/2.0 milligram (mg) LY2189265</arm_group_label>
    <arm_group_label>1.0/1.0 milligram (mg) LY2189265</arm_group_label>
    <arm_group_label>0.5/1.0 milligram (mg) LY2189265</arm_group_label>
    <other_name>Dulaglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus &gt;3 months by history prior to entering the trial, based on
             disease diagnostic criteria from the American Diabetes Association (ADA 2007).

          -  Men or women 18 years of age or older. Women must have a negative pregnancy test and
             be willing to use birth control during study duration and one month post.

          -  Have glycosylated hemoglobin (HbA1c) of &gt;7.0% to ≤10.5% as determined by central
             laboratory at screening.

          -  Have a body mass index (BMI) between 27 and 40 kilograms/meter squared (kg/m^2),
             inclusive.

          -  Have been on the same doses for 3 months of any approved combination of 2 oral
             antihyperglycemic medications in any combination of the following: sulfonylureas (e.g.
             Chlorpropamide or Diabinese, Glimepiride or Amaryl, Tolbutamide or Orinase, Tolazamide
             or Tolinase, Glipizide or Glucotrol, Glyburide also known as Micronase, Diabeta, or
             Glynase), biguanides (e.g. Glucophage or metformin), thiazolidinediones (e.g.
             Rosiglitazone or Avandia, or Pioglitazone or Actos), or dipeptidyl peptidase 4
             (DPP-IV) inhibitors (e.g. Sitagliptin or Januvia). A combination pill of any 2 of
             these drugs is allowed (1 only), (e.g. Metformin and Glipizide or Metaglip), (e.g.
             Metformin and Glyburide or Glucovance), (e.g. Pioglitazone and Glimepiride or
             Duetact), or (e.g. Sitagliptin and Metformin or Janumet).

        Exclusion Criteria:

          -  Have known Type 1 Diabetes Mellitus

          -  Have taken glucagon-like peptide-1 (GLP-1) or any GLP-1 analog drug (Byetta)

          -  Have a history of unstable angina, heart attack (myocardial infarction), heart
             arrhythmia (ventricular), congestive heart failure, or other coronary intervention
             (percutaneous transluminal coronary angioplasty [PTCA], open heart surgery, or
             coronary artery bypass graft [CABG]), a transient ischemic attack (TIA) or stroke
             (cerebrovascular accident) in the last 6 months prior to screening.

          -  Have acute or chronic hepatitis or elevated liver function tests (alanine
             transaminase), a history of chronic or recurrent pancreatitis. Have renal disease or a
             serum creatinine (blood test) &gt;2 milligrams per deciliter (mg/dL). If taking
             biguanides (e.g. metformin or Glucophage), or DPP-IV inhibitors (e.g. Sitagliptin or
             Januvia or Janumet), creatinine must be ≤1.5 mg/dL.

          -  Currently taking prescription or over the counter medications to prevent weight loss.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manatí</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toa Baja</city>
        <zip>00949</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>October 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2014</results_first_posted>
  <disposition_first_submitted>December 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2009</disposition_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1.0/2.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>1.0/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
        </group>
        <group group_id="P3">
          <title>0.5/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who received at least one dose of LY2189265 or Placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>1.0/2.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>1.0/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>0.5/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.49" spread="11.28"/>
                    <measurement group_id="B2" value="57.46" spread="11.72"/>
                    <measurement group_id="B3" value="58.65" spread="11.69"/>
                    <measurement group_id="B4" value="55.96" spread="12.49"/>
                    <measurement group_id="B5" value="56.65" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.43" spread="0.99"/>
                    <measurement group_id="B2" value="8.25" spread="0.99"/>
                    <measurement group_id="B3" value="8.25" spread="0.89"/>
                    <measurement group_id="B4" value="8.05" spread="0.82"/>
                    <measurement group_id="B5" value="8.24" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per square meters (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.24" spread="4.11"/>
                    <measurement group_id="B2" value="33.85" spread="3.95"/>
                    <measurement group_id="B3" value="33.70" spread="4.11"/>
                    <measurement group_id="B4" value="33.89" spread="4.31"/>
                    <measurement group_id="B5" value="33.92" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.60" spread="18.41"/>
                    <measurement group_id="B2" value="96.68" spread="16.51"/>
                    <measurement group_id="B3" value="94.76" spread="16.53"/>
                    <measurement group_id="B4" value="94.74" spread="15.21"/>
                    <measurement group_id="B5" value="96.18" spread="16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.63" spread="6.92"/>
                    <measurement group_id="B2" value="8.13" spread="5.43"/>
                    <measurement group_id="B3" value="8.97" spread="7.62"/>
                    <measurement group_id="B4" value="7.48" spread="5.41"/>
                    <measurement group_id="B5" value="8.30" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus</title>
        <description>Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glycosylated hemoglobin (HbA1c) data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus</title>
          <description>Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glycosylated hemoglobin (HbA1c) data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.12"/>
                    <measurement group_id="O2" value="-1.29" spread="0.12"/>
                    <measurement group_id="O3" value="-1.28" spread="0.12"/>
                    <measurement group_id="O4" value="-0.27" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose</title>
        <description>Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable fasting blood glucose data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose</title>
          <description>Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable fasting blood glucose data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.33"/>
                    <measurement group_id="O2" value="-2.04" spread="0.34"/>
                    <measurement group_id="O3" value="-2.09" spread="0.34"/>
                    <measurement group_id="O4" value="-0.49" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)</title>
        <description>Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie [Kcal], 103 grams [g] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting [0]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glucose excursion data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)</title>
          <description>Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie [Kcal], 103 grams [g] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting [0]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glucose excursion data.</population>
          <units>millimoles per liter (mmol/L)*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=63, n=62, n=66, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.03" spread="5.02"/>
                    <measurement group_id="O2" value="11.12" spread="4.77"/>
                    <measurement group_id="O3" value="10.32" spread="4.93"/>
                    <measurement group_id="O4" value="10.76" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=52, n=56, n=54, n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" spread="4.58"/>
                    <measurement group_id="O2" value="9.92" spread="5.32"/>
                    <measurement group_id="O3" value="8.85" spread="4.94"/>
                    <measurement group_id="O4" value="10.94" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles</title>
        <description>Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
        <time_frame>2 separate days in the week preceding the Baseline, Week 4, Week 8, and Week 16 visits.</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable blood glucose (SMBG) data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles</title>
          <description>Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable blood glucose (SMBG) data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=34, n=38, n=35, n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.19" spread="5.85"/>
                    <measurement group_id="O2" value="-35.94" spread="5.30"/>
                    <measurement group_id="O3" value="-31.66" spread="5.36"/>
                    <measurement group_id="O4" value="-8.10" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=34, n=41, n=38, n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.00" spread="5.88"/>
                    <measurement group_id="O2" value="-40.68" spread="5.43"/>
                    <measurement group_id="O3" value="-36.02" spread="5.35"/>
                    <measurement group_id="O4" value="-14.58" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=41, n=50, n=46, n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.49" spread="5.89"/>
                    <measurement group_id="O2" value="-41.79" spread="5.25"/>
                    <measurement group_id="O3" value="-32.52" spread="5.40"/>
                    <measurement group_id="O4" value="-8.67" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 4. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 8. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at Week 16. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)</title>
        <description>Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable HOMA2-%B or HOMA2-%S data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)</title>
          <description>Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable HOMA2-%B or HOMA2-%S data.</population>
          <units>percentage of HOMA2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HOMA2-%B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.61" spread="55.20"/>
                    <measurement group_id="O2" value="44.26" spread="93.89"/>
                    <measurement group_id="O3" value="39.20" spread="45.56"/>
                    <measurement group_id="O4" value="1.04" spread="41.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="18.51"/>
                    <measurement group_id="O2" value="-1.65" spread="17.19"/>
                    <measurement group_id="O3" value="0.46" spread="13.78"/>
                    <measurement group_id="O4" value="2.46" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Treatment comparison of HOMA2-%B. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <p_value_desc>Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.729</p_value>
            <p_value_desc>Treatment comparison of HOMA2-%S. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of &lt;7% or ≤6.5%</title>
        <description>Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of &lt;7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.</description>
        <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glycosylated hemoglobin (HbA1c) data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of &lt;7% or ≤6.5%</title>
          <description>Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of &lt;7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable glycosylated hemoglobin (HbA1c) data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c levels &lt;7.0%, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels ≤6.5%, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels &lt;7.0%, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="22.7"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels ≤6.5%, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels &lt;7%, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="47.0"/>
                    <measurement group_id="O4" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels ≤6.5%, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels &lt;7%, Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="56.1"/>
                    <measurement group_id="O4" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c levels ≤6.5%, Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
        <time_frame>Baseline, 4, 8, and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable body weight data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable body weight data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks (n=63, n=63, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.23"/>
                    <measurement group_id="O2" value="-1.08" spread="0.23"/>
                    <measurement group_id="O3" value="-0.50" spread="0.22"/>
                    <measurement group_id="O4" value="-0.06" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks (n=61, n=60, n=63, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="0.31"/>
                    <measurement group_id="O2" value="-1.67" spread="0.32"/>
                    <measurement group_id="O3" value="-1.39" spread="0.31"/>
                    <measurement group_id="O4" value="-0.12" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks (n=63, n=63, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="0.38"/>
                    <measurement group_id="O2" value="-1.40" spread="0.38"/>
                    <measurement group_id="O3" value="-1.58" spread="0.37"/>
                    <measurement group_id="O4" value="-0.07" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <p_value_desc>Treatment comparison at 4 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 8 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Treatment comparison at 16 weeks. P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference</title>
        <description>Mean change from baseline in waist circumference (a measure of central obesity).</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable waist circumference data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference</title>
          <description>Mean change from baseline in waist circumference (a measure of central obesity).</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable waist circumference data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="4.24"/>
                    <measurement group_id="O2" value="-1.51" spread="4.56"/>
                    <measurement group_id="O3" value="-1.33" spread="4.21"/>
                    <measurement group_id="O4" value="0.20" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-values ≤0.05 were considered significant. No adjustment for multiple comparisons was performed.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea and Dyspepsia Measured by Visual Analog Scale</title>
        <description>Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.</description>
        <time_frame>One week before and one week after each of the Baseline and Week 4 and Week 8 and Week 16 visits</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable nausea or dyspepsia (abdominal pain and bloating) data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea and Dyspepsia Measured by Visual Analog Scale</title>
          <description>Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable nausea or dyspepsia (abdominal pain and bloating) data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea, Week before Baseline (n=52, 57, 61, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="10.50"/>
                    <measurement group_id="O2" value="3.56" spread="6.46"/>
                    <measurement group_id="O3" value="3.70" spread="5.76"/>
                    <measurement group_id="O4" value="3.35" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week after Baseline (n=42, 46, 50, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="8.58"/>
                    <measurement group_id="O2" value="3.85" spread="6.46"/>
                    <measurement group_id="O3" value="3.86" spread="5.96"/>
                    <measurement group_id="O4" value="2.25" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week before Baseline (n=52, 57, 61, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="11.37"/>
                    <measurement group_id="O2" value="3.55" spread="9.14"/>
                    <measurement group_id="O3" value="4.04" spread="7.15"/>
                    <measurement group_id="O4" value="3.63" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week after Baseline (n=42, 46, 50, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="9.41"/>
                    <measurement group_id="O2" value="4.89" spread="13.35"/>
                    <measurement group_id="O3" value="4.51" spread="8.60"/>
                    <measurement group_id="O4" value="2.86" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week before Baseline (n=52, 57, 61, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" spread="16.80"/>
                    <measurement group_id="O2" value="8.11" spread="18.04"/>
                    <measurement group_id="O3" value="10.21" spread="15.32"/>
                    <measurement group_id="O4" value="9.30" spread="18.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week after Baseline (n=42, 46, 50, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" spread="12.90"/>
                    <measurement group_id="O2" value="10.10" spread="16.64"/>
                    <measurement group_id="O3" value="9.17" spread="15.61"/>
                    <measurement group_id="O4" value="8.42" spread="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week before Week 4 (n=42, 55, 52, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="10.89"/>
                    <measurement group_id="O2" value="6.88" spread="11.47"/>
                    <measurement group_id="O3" value="7.97" spread="15.33"/>
                    <measurement group_id="O4" value="4.10" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week after Week 4 (n=49, 58, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.13" spread="24.52"/>
                    <measurement group_id="O2" value="12.28" spread="19.46"/>
                    <measurement group_id="O3" value="7.91" spread="12.39"/>
                    <measurement group_id="O4" value="4.10" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week before Week 4 (n=42, 55, 52, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" spread="9.53"/>
                    <measurement group_id="O2" value="7.74" spread="13.89"/>
                    <measurement group_id="O3" value="6.38" spread="11.13"/>
                    <measurement group_id="O4" value="4.45" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week after Week 4 (n=49, 58, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.47" spread="20.44"/>
                    <measurement group_id="O2" value="9.31" spread="15.77"/>
                    <measurement group_id="O3" value="4.94" spread="8.89"/>
                    <measurement group_id="O4" value="4.59" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week before Week 4 (n=42, 55, 52, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.56" spread="19.51"/>
                    <measurement group_id="O2" value="12.00" spread="19.17"/>
                    <measurement group_id="O3" value="9.95" spread="13.27"/>
                    <measurement group_id="O4" value="7.96" spread="15.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week after Week 4 (n=49, 58, 59, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.90" spread="25.61"/>
                    <measurement group_id="O2" value="13.40" spread="21.15"/>
                    <measurement group_id="O3" value="10.23" spread="13.88"/>
                    <measurement group_id="O4" value="8.40" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week before Week 8 (n=50, 51, 55, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="20.26"/>
                    <measurement group_id="O2" value="5.45" spread="10.63"/>
                    <measurement group_id="O3" value="7.39" spread="13.53"/>
                    <measurement group_id="O4" value="6.11" spread="12.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week after Week 8 (n=50, 54, 54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="12.88"/>
                    <measurement group_id="O2" value="5.57" spread="11.50"/>
                    <measurement group_id="O3" value="8.69" spread="13.41"/>
                    <measurement group_id="O4" value="5.30" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week before Week 8 (n=50, 51, 55, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.76" spread="19.06"/>
                    <measurement group_id="O2" value="5.76" spread="12.47"/>
                    <measurement group_id="O3" value="5.12" spread="9.01"/>
                    <measurement group_id="O4" value="6.65" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week after Week 8 (n=50, 54, 54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.97" spread="14.72"/>
                    <measurement group_id="O2" value="6.87" spread="14.56"/>
                    <measurement group_id="O3" value="6.26" spread="11.93"/>
                    <measurement group_id="O4" value="6.38" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week before Week 8 (n=50, 51, 55, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65" spread="26.41"/>
                    <measurement group_id="O2" value="10.93" spread="17.92"/>
                    <measurement group_id="O3" value="11.58" spread="20.13"/>
                    <measurement group_id="O4" value="10.12" spread="19.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week after Week 8 (n=50, 54, 54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30" spread="18.66"/>
                    <measurement group_id="O2" value="11.18" spread="19.56"/>
                    <measurement group_id="O3" value="14.50" spread="20.95"/>
                    <measurement group_id="O4" value="10.34" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week before Week 16 (n=45, 49, 52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.68" spread="17.79"/>
                    <measurement group_id="O2" value="3.31" spread="5.53"/>
                    <measurement group_id="O3" value="6.36" spread="10.82"/>
                    <measurement group_id="O4" value="5.88" spread="14.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Week after Week 16 (n=45, 48, 49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.09" spread="17.62"/>
                    <measurement group_id="O2" value="5.73" spread="10.80"/>
                    <measurement group_id="O3" value="7.77" spread="12.25"/>
                    <measurement group_id="O4" value="3.40" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week before Week 16 (n=45, 49, 52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="9.48"/>
                    <measurement group_id="O2" value="5.68" spread="11.09"/>
                    <measurement group_id="O3" value="6.26" spread="12.89"/>
                    <measurement group_id="O4" value="6.17" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab pain, Week after Week 16 (n=45, 48, 49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" spread="14.28"/>
                    <measurement group_id="O2" value="5.99" spread="11.53"/>
                    <measurement group_id="O3" value="6.44" spread="12.58"/>
                    <measurement group_id="O4" value="5.19" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week before Week 16 (n=45, 49, 52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.57" spread="18.93"/>
                    <measurement group_id="O2" value="9.06" spread="16.78"/>
                    <measurement group_id="O3" value="12.26" spread="20.06"/>
                    <measurement group_id="O4" value="9.30" spread="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week after Week 16 (n=45, 48, 49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.06" spread="20.46"/>
                    <measurement group_id="O2" value="11.11" spread="19.62"/>
                    <measurement group_id="O3" value="14.04" spread="22.26"/>
                    <measurement group_id="O4" value="8.84" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores</title>
        <description>Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.</description>
        <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable Gastroparesis Cardinal Symptom Index (GCSI) questionnaire data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores</title>
          <description>Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable Gastroparesis Cardinal Symptom Index (GCSI) questionnaire data. For Week 16 data, last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stomach fullness, Week 4 (n=62, n=60, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.51"/>
                    <measurement group_id="O2" value="0.57" spread="1.35"/>
                    <measurement group_id="O3" value="0.62" spread="1.26"/>
                    <measurement group_id="O4" value="0.35" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach fullness, Week 8 (n=59, n=60, n=59, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.65"/>
                    <measurement group_id="O2" value="0.30" spread="1.33"/>
                    <measurement group_id="O3" value="0.71" spread="1.54"/>
                    <measurement group_id="O4" value="0.25" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach fullness, Week 16 (n=63, n=62, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.58"/>
                    <measurement group_id="O2" value="0.27" spread="1.28"/>
                    <measurement group_id="O3" value="0.51" spread="1.34"/>
                    <measurement group_id="O4" value="0.15" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week 4 (n=62, n=60, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.10"/>
                    <measurement group_id="O2" value="0.28" spread="0.93"/>
                    <measurement group_id="O3" value="0.19" spread="0.91"/>
                    <measurement group_id="O4" value="0.28" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week 8 (n=59, n=60, n=60, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.34"/>
                    <measurement group_id="O2" value="0.13" spread="1.02"/>
                    <measurement group_id="O3" value="0.14" spread="1.32"/>
                    <measurement group_id="O4" value="0.18" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating, Week 16 (n=63, n=62, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.04"/>
                    <measurement group_id="O2" value="0.11" spread="0.94"/>
                    <measurement group_id="O3" value="0.32" spread="1.32"/>
                    <measurement group_id="O4" value="0.28" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting, Week 4 (n=62, n=60, n=64, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.71"/>
                    <measurement group_id="O2" value="0.19" spread="0.71"/>
                    <measurement group_id="O3" value="0.22" spread="0.52"/>
                    <measurement group_id="O4" value="0.03" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting, Week 8 (n=59, n=60, n=60, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.97"/>
                    <measurement group_id="O2" value="0.04" spread="0.64"/>
                    <measurement group_id="O3" value="0.28" spread="0.62"/>
                    <measurement group_id="O4" value="0.02" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting, Week 16 (n=63, n=62, n=65, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.64"/>
                    <measurement group_id="O2" value="-0.01" spread="0.59"/>
                    <measurement group_id="O3" value="0.27" spread="0.48"/>
                    <measurement group_id="O4" value="-0.01" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Hypoglycemic Event</title>
        <description>A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of &lt;50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 4, 8, and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Hypoglycemic Event</title>
          <description>A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of &lt;50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Documented Hypoglycemic Event, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Hypoglycemic Event, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Hypoglycemic Event, Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hypoglycemic Event, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hypoglycemic Event, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hypoglycemic Event, Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hypoglycemia Per 30 Days</title>
        <description>Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hypoglycemia Per 30 Days</title>
          <description>Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo.</population>
          <units>events per participant per 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.29"/>
                    <measurement group_id="O2" value="0.80" spread="1.60"/>
                    <measurement group_id="O3" value="0.70" spread="1.18"/>
                    <measurement group_id="O4" value="0.24" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipids</title>
        <description>Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable lipid data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipids</title>
          <description>Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.</description>
          <population>Participants who received at least one dose of LY2189265 or Placebo with evaluable lipid data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol (n=61, n=60, n=60, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-3.44" upper_limit="2.28"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-1.37" upper_limit="2.69"/>
                    <measurement group_id="O3" value="-0.09" lower_limit="-2.18" upper_limit="4.77"/>
                    <measurement group_id="O4" value="0.18" lower_limit="-1.91" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-Cholesterol (n=61, n=60, n=60, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" lower_limit="-2.80" upper_limit="2.23"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-1.22" upper_limit="1.58"/>
                    <measurement group_id="O3" value="-0.07" lower_limit="-1.39" upper_limit="4.27"/>
                    <measurement group_id="O4" value="0.10" lower_limit="-0.83" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-Cholesterol (n=61, n=60, n=60, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.33" upper_limit="0.41"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.37" upper_limit="0.54"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.26" upper_limit="0.23"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.24" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (n=61, n=60, n=60, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" lower_limit="-7.63" upper_limit="2.22"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-4.84" upper_limit="2.96"/>
                    <measurement group_id="O3" value="-0.16" lower_limit="-4.25" upper_limit="2.96"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-7.39" upper_limit="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</title>
        <description>The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6–point scale ranging from 1 “completely dissatisfied” to 6 “completely satisfied”; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 “all of the time” to 4 “none of the time”; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 “all of the time” to 4 “none of the time.” These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.</description>
        <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
        <population>Participants in the per-protocol population with evaluable PAM-D-S questionnaire data. The per-protocol population consisted of participants who received at least one dose of study medication, had no significant protocol violations, completed the double-blind treatment phase, and were compliant with the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</title>
          <description>The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6–point scale ranging from 1 “completely dissatisfied” to 6 “completely satisfied”; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 “all of the time” to 4 “none of the time”; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 “all of the time” to 4 “none of the time.” These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.</description>
          <population>Participants in the per-protocol population with evaluable PAM-D-S questionnaire data. The per-protocol population consisted of participants who received at least one dose of study medication, had no significant protocol violations, completed the double-blind treatment phase, and were compliant with the study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7"/>
                    <measurement group_id="O2" value="87.0"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="90.5"/>
                    <measurement group_id="O3" value="90.9"/>
                    <measurement group_id="O4" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="86.0"/>
                    <measurement group_id="O4" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Validation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</title>
        <description>This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.</description>
        <time_frame>Baseline and 4 and 8 and 16 weeks</time_frame>
        <population>The items in the Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. Therefore, no participants were analyzed for validation purposes.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Validation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire</title>
          <description>This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.</description>
          <population>The items in the Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. Therefore, no participants were analyzed for validation purposes.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)</title>
        <description>The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve [AUC] at steady state from time zero to 168 hours after study drug administration).</description>
        <time_frame>Time zero to 168 hours after study drug administration at 4, 8, and 16 weeks</time_frame>
        <population>Participants who received at least one dose of LY2189265 with evaluable LY2189265 concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0/2.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.0/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.5/1.0 Milligram (mg) LY2189265</title>
            <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)</title>
          <description>The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve [AUC] at steady state from time zero to 168 hours after study drug administration).</description>
          <population>Participants who received at least one dose of LY2189265 with evaluable LY2189265 concentration data.</population>
          <units>nanograms*hour/milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14587" spread="5674"/>
                    <measurement group_id="O2" value="7876" spread="3064"/>
                    <measurement group_id="O3" value="4488" spread="1746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1.0/2.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>1.0/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>0.5/1.0 Milligram (mg) LY2189265</title>
          <description>LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: subcutaneous (SC), once weekly (QW) for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptogenic organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

